Is it possible, that COH could only do generic work around inhibiting FTO without any ability to move it to a clinical setting, due to RAC owning the drug.
and it was decided a couple of years ago that RAC would go away and build enough pre-clinical evidence in specific cell lines along with doms work that when the time is right they come back together and combine the data sets some how is enough validation to be able to move into or through the clinic quicker?
Ann: Letter to Shareholders, page-82
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |